An FDA Advisory Committee has recommended that Pfizer be allowed to market Celebrex to children ages 2 and older who suffer from Juvenile Rheumatoid Arthritis (JRA). The panel voted 15-1 that the drug was an effective treatment and that its benefits outweighed its risks. The panel members split on the issue of safety, voting 8-7 (with one abstention) that available data does not demonstrate safety. The panel strongly recommends that the safety of Celebrex in children be monitored for 10-20 years, possibly by creating a registry of patients. Panel member Dr. Joan Bathon, rheumatologist at Johns Hopkins, said, “The feeling was short-term efficacy looked good and short-term safety was not an issue. Long-term safety is totally unknown and needs to be known.” The FDA is not required to take the advice of its expert panels, but it usually does.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.